BOULDER, Colo. -- (BUSINESS WIRE) -- Biodesix, Inc., a fully integrated molecular diagnostic company dedicated to personalizing medicine, today announced that the Phase III clinical trial data for its VeriStrat® test will be a featured abstract in the 2013 Best of ASCO meetings. Topics for the meeting are determined by a panel of medical oncology experts who select abstracts that demonstrate practice-changing science, from the 2013 Annual Meeting of the American Society of Clinical Oncology®. The series visits Chicago, Los Angeles and Boston throughout the month of August.
This year, the Best of ASCO panel has chosen to include results from the phase III clinical trial PROSE (Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer), which examines the efficacy of VeriStrat in predicting patients’ survival outcomes when treated with two common treatment choices. Notably, PROSE is the world’s first successful, prospective biomarker-stratified study in oncology to test treatment and biomarker interaction.
Presented by Principal Investigator Vanesa Gregorc, M.D., the independent trial confirmed that Biodesix’ serum protein test, VeriStrat, is a strong predictor of differential treatment benefit between erlotinib and chemotherapy for non-small cell lung cancer patients in a second-line setting. According to Dr. Gregorc, of the Department of Oncology at the Scientific Institute of the University Hospital San Raffaele in Milan, Italy, the VeriStrat test provides valuable information that helps physicians make the right treatment decisions at a critical juncture in patient management.
“Biodesix is honored that the PROSE presentation has been chosen among the hot topics to be discussed at Best of ASCO meetings this year,” said David Brunel, Chief Executive Officer of Biodesix.
VeriStrat requires only a simple blood draw and test results are returned, on average, in less than 72 hours, allowing physicians to make quick treatment decisions. Following a positive Medicare coverage decision in June, VeriStrat is now available as a covered diagnostic test to more than 49 million eligible Medicare enrollees in the U.S.
For more information about VeriStrat, visit www.veristratsupport.com.
Biodesix is a molecular diagnostics company advancing the development of innovative products for personalizing medicine. The company provides physicians with diagnostic tests for earlier disease detection, more accurate diagnosis, disease monitoring and better therapeutic guidance, which may lead to improved patient outcomes. Biodesix discovers, develops and commercializes multivariate protein diagnostics based on their proprietary mass spectrometry-based discovery platform. VeriStrat, a multivariate serum protein test, is Biodesix’ first product developed with this technology. The commercially available test provides oncologists with information to help them select between erlotinib and single-agent chemotherapy for advanced lung cancer patients. Tests are processed in Biodesix’ CLIA-certified laboratory and results are reported in less than 72 hours. In addition to developing novel diagnostics independently, the company also partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve utility of therapeutic agents. For more information on VeriStrat, please visit www.VeriStratSupport.com. For more information about Biodesix, please visit www.Biodesix.com.
This press release contains statements that are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company's financial resources will be insufficient to meet the Company's business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.